AGENUS INC — Director's Dealing 2023

May 26, 2023

SEC Form 4/A — Form 4/A

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2023-05-05

Reporting Person: AGENUS INC (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21476531	Direct

Footnotes

F1: On May 5, 2023, Agenus Inc. ("Agenus") disclosed a transaction involving 100,000 Mink Therapeutics shares. It agreed to purchase such shares from Garo Armen, the CEO and Chairman of Agenus, at Dr. Armen's original purchase price, which was lower than the market price at the time of the proposed purchase. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the Mink Therapeutics shares were returned to Dr. Armen, and the purchase price was given back to Agenus. This amendment accounts for the changes in Agenus' ownership following the reversal of this transaction.